INMB

INmune Bio Inc.

Price

$2.31

return (12m)

10.53%

p/e

-3.46

p/bv

3.13

DIVIDEND YIELD

0.00%

INMB price

INmune Bio

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment INMB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

34.69%

3 months

63.83%

1 year

10.53%

2 years

-66.18%

5 years

-88.47%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals INMB

Valuation

P/E

-3.46

Sector -4.26

Industry -4.26

P/BV

3.13

Sector 2.11

Industry 2.11

P/Revenue (PSR)

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

2.37

Sector 1.25

Industry 1.25

P/Net Current Assets

3.68

Sector -5.47

Industry -5.47

P/Working Capital

3.56

Sector -1.10

Industry -1.10

EPS

-0.68

Sector -1.94

Industry -1.94

BVPS

0.75

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

0.00%

Sector 38.90%

Industry 38.90%

EBITDA Margin

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

0.00%

Sector -36.74%

Industry -36.74%

Net Profit Margins

0.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-90.42%

Sector -61.50%

Industry -61.50%

ROA

-68.59%

Sector -63.85%

Industry -63.85%

ROIC

0.00%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.04

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

0.00

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.00

Sector -0.83

Industry -0.83

Equity/Assets

0.76

Sector 0.43

Industry 0.43

Liabilities/Assets

0.24

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-9.51%

Sector -

Industry -

Fundamentals INMB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
INMB INmune Bio Inc.	$2.31	12.96%	0.00%	-3.46	3.13	-90.42%	0.00%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

INMB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT INmune Bio

INmune Bio Inc.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2019

Time since IPO - 7 years

5

Employees

INmune Bio Inc. (United States) is listed on the Nasdaq and has a market capitalization of $63.72 million, with shareholders equity totaling $20.36 million.

The company employs approximately 5 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, INmune Bio Inc. reported $- in revenue, generating net income of $-18.41 million.

Key financial metrics include a P/E ratio of -3.46, a price-to-book (P/B) ratio of 3.13, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INMB.

Market cap

$63.72 million

Net worth

$20.36 million

$20,360,000.00

Assets

$26.84 million

$26,840,000.00

Total Shares Outstanding

27.00 million

27,000,000

Average Daily Trading Volume

$828.37 Thousand

$828,373.30

Sector

Health Care

Industry

Biotechnology

INMB

INMB revenue and profits

Financial Results INMB

DRAG THE FRAME TO SEE MORE DATA

INMB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of INmune Bio (INMB) today?

A cotação de INmune Bio (INMB) hoje está em US$ 2.31, com uma variação de 10.53% em relação ao último ano. A cotação de INmune Bio (INMB) iniciou o ano negociando na casa dos US$ 1.56 e hoje está em US$ 2.31. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de INmune Bio (INMB) e dados de ações do Ibovespa e mercados internacionais.

Quando INmune Bio (INMB) paga dividendos?

INmune Bio (INMB) não distribuiu dividendos no último ano.

Is INmune Bio (INMB) a good investment?

Atualmente, INmune Bio (INMB) está cotada a US$ 2.31, com um P/L de -3.46, representando um desvio de -355% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 10.53 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 10.53%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy INmune Bio (INMB) stock?

Investir em ações de INmune Bio (INMB) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of INmune Bio (INMB) yield today?

A rentabilidade de INmune Bio (INMB) foi de 34.69% no último mês, 10.53% no último ano e -88.47% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de INmune Bio (INMB) hoje, o investimento total seria de US$ 231.00, com base na cotação atual de US$ 2.31.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 255.32
Em 5 anos: US$ 26.63
Em 10 anos: US$ 231.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

INMB

INmune Bio Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment INMB

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING INMB WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT INmune Bio

INmune Bio Inc.

United States

11 years

2019

5

PROFIT X PRICE INMB

Financial Results INMB

INMB cash flow

Asset, Revenue and Profit Growth - INMB

INMB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions